Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > ORGANIZATION
ORGANIZATION
- 4 Cell & Gene Therapies Represent 90% of Top 100 Bills in FY2022: Payer
September 8, 2023
- Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
- Industry Calls for Clear Criteria for SaMD Reimbursement to Boost Predictability
September 5, 2023
- HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
September 4, 2023
- Only 1.2% of NSCLC Patients Receiving Gene Panel Tests: Survey
September 1, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
- As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
August 25, 2023
- Japan Citizens’ Group Objects to HPV Vaccination in Males
August 25, 2023
- JPMA Taskforce Issues Proposal on Information Supply, Drug Development for Rare Diseases
August 18, 2023
- Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
August 17, 2023
- INES Proposes Extension of Public Funding for COVID Drugs
August 7, 2023
- IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
July 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- JPA to Issue Policy Proposal to Address Lingering Supply Crisis
July 24, 2023
- More People Seek Self-Medication Tax Break in 2022
July 24, 2023
- JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
July 20, 2023
- Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…